Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (2): 134-140.DOI: 10.3969/j.issn.1673-8640.2022.02.008
Previous Articles Next Articles
GU Feng1, WU Yanfen2, ZHAO Xinhui2, HOU Zhaoyuan1, WANG Zhihong2, QI Hualin2
Received:
2021-03-18
Revised:
2021-08-09
Online:
2022-02-28
Published:
2022-03-15
CLC Number:
GU Feng, WU Yanfen, ZHAO Xinhui, HOU Zhaoyuan, WANG Zhihong, QI Hualin. Relationship between procalcitonin level and all-cause death in maintenance hemodialysis patients[J]. Laboratory Medicine, 2022, 37(2): 134-140.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.02.008
组别 | 例数 | 年龄/岁 | 性别 | BMI/(kg/m2) | 吸烟史/例 | 原发疾病 | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男性/例 | 女性/例 | 慢性肾炎/例 | 高血压肾病/例 | 糖尿病肾病/例 | 其他/例 | ||||||||||||||||||||
高PCT组 | 74 | 63±15 | 42 | 32 | 22.30(20.51~24.23) | 5 | 31 | 14 | 22 | 7 | |||||||||||||||
低PCT组 | 86 | 62±10 | 48 | 38 | 22.26(20.55~24.30) | 9 | 29 | 16 | 37 | 4 | |||||||||||||||
统计值 | 0.476 | 0.014 | -0.608 | 0.685 | 1.133 | 0.003 | 3.020 | 1.436 | |||||||||||||||||
P值 | 0.635 | 0.905 | 0.544 | 0.408 | 0.287 | 0.960 | 0.182 | 0.231 | |||||||||||||||||
组别 | 合并症 | 透析时间/年 | 相对容量清除/% | spKt/V | URR/% | ||||||||||||||||||||
高血压/例 | 糖尿病/例 | 心脏病/例 | |||||||||||||||||||||||
高PCT组 | 65 | 33 | 30 | 6(3~9) | 5.47(5.00~6.57) | 1.36(1.24~1.51) | 65.93(61.40~70.99) | ||||||||||||||||||
低PCT组 | 78 | 46 | 32 | 3(2~6) | 5.37(4.19~6.31) | 1.36(1.17~1.54) | 66.49(61.31~71.88) | ||||||||||||||||||
统计值 | 3.887 | 1.259 | 0.186 | -3.452 | -1.525 | -0.308 | -0.313 | ||||||||||||||||||
P值 | 0.558 | 0.262 | 0.666 | 0.001 | 0.127 | 0.758 | 0.754 | ||||||||||||||||||
组别 | 收缩压/kPa | 舒张压/kPa | Hb/(g/L) | Alb/(g/L) | WBC计数/(×109/L) | ||||||||||||||||||||
高PCT组 | 19.42(18.35~21.15) | 10.37(9.84~11.31) | 102±19 | 38.9±3.9 | 6.02(4.02~7.13) | ||||||||||||||||||||
低PCT组 | 19.82(18.89~21.55) | 10.37(9.98~11.17) | 100±17 | 39.0±2.7 | 6.16(5.03~7.15) | ||||||||||||||||||||
统计值 | -0.757 | -0.234 | 0.814 | 0.516 | -0.518 | ||||||||||||||||||||
P值 | 0.449 | 0.815 | 0.417 | 0.606 | 0.604 | ||||||||||||||||||||
组别 | MO#/(×109/L) | TB/(μmol/L) | Na+/(mmol/L) | Cr/(μmol/L) | UA/(mmol/L) | ||||||||||||||||||||
高PCT组 | 0.43(0.33~0.52) | 5.8(4.5~7.0) | 136(135~138) | 989±271 | 0.505(0.455~0.551) | ||||||||||||||||||||
低PCT组 | 0.42(0.32~0.50) | 5.6(4.6~6.9) | 137(135~139) | 950±224 | 0.484(0.418~0.553) | ||||||||||||||||||||
统计值 | -0.575 | -0.163 | -0.474 | 0.974 | -1.290 | ||||||||||||||||||||
P值 | 0.565 | 0.871 | 0.635 | 0.332 | 0.197 | ||||||||||||||||||||
组别 | Ca×P | TG/(mmol/L) | TC/(mmol/L) | LDL-C/(mmol/L) | HDL-C/(mmol/L) | ||||||||||||||||||||
高PCT组 | 4.67(3.94~5.58) | 1.91(1.25~2.97) | 3.56(2.95~4.51) | 2.2(1.6~2.7) | 0.88(0.72~1.03) | ||||||||||||||||||||
低PCT组 | 4.88(3.67~5.66) | 1.51(1.21~2.39) | 3.71(3.21~4.32) | 2.3(1.9~2.8) | 0.93(0.79~1.10) | ||||||||||||||||||||
统计值 | -0.255 | -1.790 | -0.871 | -1.605 | -1.912 | ||||||||||||||||||||
P值 | 0.799 | 0.073 | 0.384 | 0.109 | 0.056 | ||||||||||||||||||||
组别 | CRP/(mg/L) | NT-proBNP/(pg/mL) | Vit D/(ng/mL) | NYHA分级 | |||||||||||||||||||||
Ⅱ级/例 | Ⅲ~Ⅳ级/例 | ||||||||||||||||||||||||
高PCT组 | 1.98(0.95~4.36) | 6 270(3 550~13 395) | 14.8±5.8 | 26 | 29 | ||||||||||||||||||||
低PCT组 | 0.99(0.62~1.95) | 6 124(2 439~17 985) | 13.6±6.0 | 39 | 26 | ||||||||||||||||||||
统计值 | -4.095 | -0.260 | 1.229 | 1.720 | 1.141 | ||||||||||||||||||||
P值 | 0.000 | 0.795 | 0.221 | 0.190 | 0.234 |
组别 | 例数 | 年龄/岁 | 性别 | BMI/(kg/m2) | 吸烟史/例 | 原发疾病 | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男性/例 | 女性/例 | 慢性肾炎/例 | 高血压肾病/例 | 糖尿病肾病/例 | 其他/例 | ||||||||||||||||||||
高PCT组 | 74 | 63±15 | 42 | 32 | 22.30(20.51~24.23) | 5 | 31 | 14 | 22 | 7 | |||||||||||||||
低PCT组 | 86 | 62±10 | 48 | 38 | 22.26(20.55~24.30) | 9 | 29 | 16 | 37 | 4 | |||||||||||||||
统计值 | 0.476 | 0.014 | -0.608 | 0.685 | 1.133 | 0.003 | 3.020 | 1.436 | |||||||||||||||||
P值 | 0.635 | 0.905 | 0.544 | 0.408 | 0.287 | 0.960 | 0.182 | 0.231 | |||||||||||||||||
组别 | 合并症 | 透析时间/年 | 相对容量清除/% | spKt/V | URR/% | ||||||||||||||||||||
高血压/例 | 糖尿病/例 | 心脏病/例 | |||||||||||||||||||||||
高PCT组 | 65 | 33 | 30 | 6(3~9) | 5.47(5.00~6.57) | 1.36(1.24~1.51) | 65.93(61.40~70.99) | ||||||||||||||||||
低PCT组 | 78 | 46 | 32 | 3(2~6) | 5.37(4.19~6.31) | 1.36(1.17~1.54) | 66.49(61.31~71.88) | ||||||||||||||||||
统计值 | 3.887 | 1.259 | 0.186 | -3.452 | -1.525 | -0.308 | -0.313 | ||||||||||||||||||
P值 | 0.558 | 0.262 | 0.666 | 0.001 | 0.127 | 0.758 | 0.754 | ||||||||||||||||||
组别 | 收缩压/kPa | 舒张压/kPa | Hb/(g/L) | Alb/(g/L) | WBC计数/(×109/L) | ||||||||||||||||||||
高PCT组 | 19.42(18.35~21.15) | 10.37(9.84~11.31) | 102±19 | 38.9±3.9 | 6.02(4.02~7.13) | ||||||||||||||||||||
低PCT组 | 19.82(18.89~21.55) | 10.37(9.98~11.17) | 100±17 | 39.0±2.7 | 6.16(5.03~7.15) | ||||||||||||||||||||
统计值 | -0.757 | -0.234 | 0.814 | 0.516 | -0.518 | ||||||||||||||||||||
P值 | 0.449 | 0.815 | 0.417 | 0.606 | 0.604 | ||||||||||||||||||||
组别 | MO#/(×109/L) | TB/(μmol/L) | Na+/(mmol/L) | Cr/(μmol/L) | UA/(mmol/L) | ||||||||||||||||||||
高PCT组 | 0.43(0.33~0.52) | 5.8(4.5~7.0) | 136(135~138) | 989±271 | 0.505(0.455~0.551) | ||||||||||||||||||||
低PCT组 | 0.42(0.32~0.50) | 5.6(4.6~6.9) | 137(135~139) | 950±224 | 0.484(0.418~0.553) | ||||||||||||||||||||
统计值 | -0.575 | -0.163 | -0.474 | 0.974 | -1.290 | ||||||||||||||||||||
P值 | 0.565 | 0.871 | 0.635 | 0.332 | 0.197 | ||||||||||||||||||||
组别 | Ca×P | TG/(mmol/L) | TC/(mmol/L) | LDL-C/(mmol/L) | HDL-C/(mmol/L) | ||||||||||||||||||||
高PCT组 | 4.67(3.94~5.58) | 1.91(1.25~2.97) | 3.56(2.95~4.51) | 2.2(1.6~2.7) | 0.88(0.72~1.03) | ||||||||||||||||||||
低PCT组 | 4.88(3.67~5.66) | 1.51(1.21~2.39) | 3.71(3.21~4.32) | 2.3(1.9~2.8) | 0.93(0.79~1.10) | ||||||||||||||||||||
统计值 | -0.255 | -1.790 | -0.871 | -1.605 | -1.912 | ||||||||||||||||||||
P值 | 0.799 | 0.073 | 0.384 | 0.109 | 0.056 | ||||||||||||||||||||
组别 | CRP/(mg/L) | NT-proBNP/(pg/mL) | Vit D/(ng/mL) | NYHA分级 | |||||||||||||||||||||
Ⅱ级/例 | Ⅲ~Ⅳ级/例 | ||||||||||||||||||||||||
高PCT组 | 1.98(0.95~4.36) | 6 270(3 550~13 395) | 14.8±5.8 | 26 | 29 | ||||||||||||||||||||
低PCT组 | 0.99(0.62~1.95) | 6 124(2 439~17 985) | 13.6±6.0 | 39 | 26 | ||||||||||||||||||||
统计值 | -4.095 | -0.260 | 1.229 | 1.720 | 1.141 | ||||||||||||||||||||
P值 | 0.000 | 0.795 | 0.221 | 0.190 | 0.234 |
项目 | 单因素回归分析 | 多因素回归分析 | |||||
---|---|---|---|---|---|---|---|
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | ||
TG | 1.225 | 0.998~1.505 | 0.052 | ||||
HDL-C | 0.376 | 0.118~1.201 | 0.099 | ||||
CRP | 1.182 | 1.043~1.339 | 0.009 | 1.182 | 1.043~1.339 | 0.009 |
项目 | 单因素回归分析 | 多因素回归分析 | |||||
---|---|---|---|---|---|---|---|
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | ||
TG | 1.225 | 0.998~1.505 | 0.052 | ||||
HDL-C | 0.376 | 0.118~1.201 | 0.099 | ||||
CRP | 1.182 | 1.043~1.339 | 0.009 | 1.182 | 1.043~1.339 | 0.009 |
项目 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
HR①值 | 95%CI | P值 | HR①值 | 95%CI | P值 | ||
年龄 | 3.202 | 1.428~7.183 | 0.005 | ||||
合并高血压 | 0.245 | 0.108~0.560 | 0.001 | ||||
Alb | 9.996 | 2.980~33.530 | 0.000 | 6.279 | 1.758~22.420 | 0.005 | |
WBC计数 | 0.353 | 0.157~0.792 | 0.012 | ||||
项目 | 单因素分析 | 多因素分析 | |||||
HR①值 | 95%CI | P值 | HR①值 | 95%CI | P值 | ||
MO# | 3.607 | 1.353~9.621 | 0.011 | 3.790 | 1.294~11.107 | 0.015 | |
TB | 3.265 | 0.980~10.880 | 0.055 | ||||
Cr | 0.388 | 0.161~0.936 | 0.035 | ||||
UA | 0.303 | 0.133~0.686 | 0.005 | ||||
PCT | 3.097 | 1.284~7.470 | 0.012 | 4.409 | 1.757~11.064 | 0.002 | |
PCT(连续型变量) | 7.099 | 2.418~20.842 | 0.000 | ||||
TG | 0.166 | 0.071~0.387 | 0.000 | 0.219 | 0.091~0.527 | 0.001 | |
TC | 0.200 | 0.069~0.582 | 0.003 | ||||
HDL-C | 0.354 | 0.152~0.829 | 0.017 | ||||
CRP | 5.751 | 1.976~16.739 | 0.001 | ||||
NT-proBNP | 5.829 | 2.623~12.953 | 0.000 | 2.618 | 1.073~6.389 | 0.034 |
项目 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
HR①值 | 95%CI | P值 | HR①值 | 95%CI | P值 | ||
年龄 | 3.202 | 1.428~7.183 | 0.005 | ||||
合并高血压 | 0.245 | 0.108~0.560 | 0.001 | ||||
Alb | 9.996 | 2.980~33.530 | 0.000 | 6.279 | 1.758~22.420 | 0.005 | |
WBC计数 | 0.353 | 0.157~0.792 | 0.012 | ||||
项目 | 单因素分析 | 多因素分析 | |||||
HR①值 | 95%CI | P值 | HR①值 | 95%CI | P值 | ||
MO# | 3.607 | 1.353~9.621 | 0.011 | 3.790 | 1.294~11.107 | 0.015 | |
TB | 3.265 | 0.980~10.880 | 0.055 | ||||
Cr | 0.388 | 0.161~0.936 | 0.035 | ||||
UA | 0.303 | 0.133~0.686 | 0.005 | ||||
PCT | 3.097 | 1.284~7.470 | 0.012 | 4.409 | 1.757~11.064 | 0.002 | |
PCT(连续型变量) | 7.099 | 2.418~20.842 | 0.000 | ||||
TG | 0.166 | 0.071~0.387 | 0.000 | 0.219 | 0.091~0.527 | 0.001 | |
TC | 0.200 | 0.069~0.582 | 0.003 | ||||
HDL-C | 0.354 | 0.152~0.829 | 0.017 | ||||
CRP | 5.751 | 1.976~16.739 | 0.001 | ||||
NT-proBNP | 5.829 | 2.623~12.953 | 0.000 | 2.618 | 1.073~6.389 | 0.034 |
[1] |
DREW D A, WEINER D E, TIGHIOUART H, et al. Cognitive function and all-cause mortality in maintenance hemodialysis patients[J]. Am J Kidney Dis, 2015, 65(2):303-311.
DOI URL |
[2] |
MANDIC A, CAVAR I, SKORO I, et al. Body composition and inflammation in hemodialysis patients[J]. Ther Apher Dial, 2017, 21(6):556-564.
DOI URL |
[3] |
CARRERO J J, STENVINKEL P. Inflammation in end-stage renal disease-what have we learned in 10 years?[J]. Semin Dial, 2010, 23(5):498-509.
DOI URL |
[4] | 胡美玲, 蒙如庆. 维持性血液透析患者微炎症状态的治疗进展[J]. 医学综述, 2019, 25(1):87-92. |
[5] | 侯凡凡, 马志刚, 梅长林, 等. 中国五省市自治区慢性肾脏病患者心血管疾病的患病率调查[J]. 中华医学杂志, 2005, 85(7):458-463. |
[6] |
VILLANUEVA M P, MOLLAR A, PALAU P, et al. Procalcitonin and long-term prognosis after an admission for acute heart failure[J]. Eur J Intern Med, 2015, 26(1):42-48.
DOI URL |
[7] |
ASSICOT M, GENDREL D, CARSIN H, et al. High serum procalcitonin concentrations in patients with sepsis and infection[J]. Lancet, 1993, 341(8844):515-518.
DOI URL |
[8] | 顾峰, 吴艳芬, 王志宏, 等. 降钙素原在维持性血液透析合并慢性心力衰竭患者诊断中的价值[J]. 同济大学学报(医学版), 2020, 41(5):617-624. |
[9] |
SARAN R, ROBINSON B, ABBOTT K C, et al. US renal data system 2018 annual data report:epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2020, 75(1 Suppl 1):A6-A7.
DOI URL |
[10] | 钱香蓓, 吴智明. 血液透析患者血清镁与身体组成成分及生存率的相关性[J]. 检验医学, 2021, 36(8):823-827. |
[11] |
TURGUTALP K, OZTURK S, ARICI M, et al. Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19[J]. BMC Nephrology, 2021, 22(1):29.
DOI URL |
[12] | 陈力平, 冯明. NLR联合CRP与PCT对慢性肾衰竭维持性血液透析患者细菌感染的诊断价值[J]. 中华医院感染学杂志, 2021, 31(12):1861-1864. |
[13] |
XU N, BO Q, SHAO R, et al. Chitinase-3-like-1 promotes M2 macrophage differentiation and induces choroidal neovascularization in neovascular age-related macular degeneration[J]. Invest Ophthalmol Vis Sci, 2019, 60(14):4596-4605.
DOI URL |
[14] |
WHANG K T, VATH S D, BECKER K L, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis[J]. Shock, 2000, 14(1):73-78.
DOI URL |
[15] |
LIAPPIS A P, GIBBS K W, NYLEN E S, et al. Exogenous procalcitonin evokes a pro-inflammatory cytokine response[J]. Inflamm Res, 2011, 60(2):203-207.
DOI URL |
[16] | 雷莹, 张云芳, 钟碧贤, 等. 不同透析龄的血液透析患者死亡相关危险因素分析[J]. 中华肾脏病杂志, 2019, 35(2):147-149. |
[17] |
CANBAY A, CELEBI O O, CELEBI S, et al. Procalcitonin:a marker of heart failure[J]. Acta Cardiol, 2015, 70(4):473-478.
DOI URL |
[18] | 李培培. 除外感染的充血性心力衰竭患者血清降钙素原水平的意义及主要影响因素[D]. 长春:吉林大学, 2019. |
[19] |
ZSOM L, FALUDI M, FÜLÖP T, et al. The association of overhydration with chronic inflammation in chronic maintenance hemodiafiltration patients[J]. Hemodial Int, 2019, 23(3):384-391.
DOI URL |
[20] |
PEARSON T A, MENSAH G A, ALEXANDER R W, et al. Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation, 2003, 107(3):499-511.
DOI URL |
[21] | CONTI G, AMORE A, CHIESA M, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis[J]. J Nephrol, 2005, 18(3):282-288. |
[22] | SONG K K, ZHAO D L, WANG Y D, et al. Analysis of factors associated with death in maintenance hemodialysis patients:a multicenter study in China[J]. Chin Med J(Engl), 2017, 130(8):885-891. |
[23] |
OLIVEIRA E A, CHEUNG W W, TOMA K G, et al. Muscle wasting in chronic kidney disease[J]. Pediatr Nephrol, 2018, 33(5):789-798.
DOI URL |
[24] |
JIA T, GAMA AXELSSON T, HEIMBÜRGER O, et al. IGF-1 and survival in ESRD[J]. Clin J Am Soc Nephrol, 2014, 9(1):120-127.
DOI URL |
[25] | 尹忠诚, 吕梅月, 濮红梅. 血液透析患者外周血单核细胞COX-2的表达及其与炎症细胞因子水平的关系[J]. 中国血液净化, 2009, 8(12):649-651. |
[26] |
XIANG F, CHEN R, CAO X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients:a prospective cohort study[J]. Hemodial Int, 2018, 22(1):82-92.
DOI URL |
[27] |
HARRISON T G, SHUKALEK C B, HEMMELGARN B R, et al. Association of NT-proBNP and BNP with future clinical outcomes in patients with ESKD:a systematic review and meta-analysis[J]. Am J Kidney Dis, 2020, 76(2):233-247.
DOI URL |
[28] |
JACOBS L H, MINGELS A M, WODZIG W K, et al. Renal dysfunction,hemodialysis,and the NT-proBNP/BNP ratio[J]. Am J Clin Pathol, 2010, 134(3):516-517.
DOI URL |
[29] | 吕玉凤, 刘必成. 透析患者心血管疾病危险因素的逆流行病学现象[J]. 中华肾脏病杂志, 2006, 22(3):183-186. |
[1] | LI Li, SUN Haiyan, LI Yuanrui, DOU Min, TANG Wen, JIANG Limin, SHEN Lisong. Changes and clinical roles of perioperative NT-proBNP and PCT in children with congenital heart disease [J]. Laboratory Medicine, 2023, 38(6): 524-531. |
[2] | ZHAI Shana, SUN Qinghai, YU Yongwu, YE Fang, LIU Maodong. Influence of vancomycin combined with meropenem on serum TNF-α,PCT,IL-6 and peritoneal fluid WBC count in PDRP patients [J]. Laboratory Medicine, 2022, 37(4): 360-364. |
[3] | HE Xuelian, HE Ziyi, LIU Yueyang, YU Yanzhi, ZHANG Siying. Role of line chart model based on peripheral blood-derived inflammation markers in early diagnosis of neonatal septicemia [J]. Laboratory Medicine, 2022, 37(10): 921-927. |
[4] | ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193. |
[5] | PAN Xilong, XU Zhiyuan, XIE Feng, LI Dan. Role of procalcitonin in the diagnosis of different sepsis [J]. Laboratory Medicine, 2021, 36(12): 1215-1218. |
[6] | ZHU Chuanxin, ZHOU Yuping, ZHOU Qin, ZHOU Guifeng. Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19 [J]. Laboratory Medicine, 2021, 36(1): 53-56. |
[7] | ZHAO Minghai, LI Xin, WEI Dong, LUO Min, ZHANG Yajie, YANG Yiqi, ZHENG Lei. Influence of dry heat inactive treatment for the determination of inflammatory indicators related with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(9): 924-927. |
[8] | LU Xiufen, HE Zhijun, LIU Qiting, FENG Zhongxin, MA Sheng. Serum procalcitonin and urine endotoxin determinations for guiding CAUTI antimicrobial therapy [J]. Laboratory Medicine, 2020, 35(7): 686-690. |
[9] | LIU Ruilai, SHANG Anquan, GUAN Ming. Diagnostic roles of HNL,PCT and TRAIL in bloodstream infection of patients with hematological diseases [J]. Laboratory Medicine, 2020, 35(12): 1277-1280. |
[10] | MA Caiyan, LAI Wenqiang, CHEN Xiaoping. Roles of PCT,HNL and CD64 in the diagnosis of bacterial infection [J]. Laboratory Medicine, 2019, 34(5): 433-436. |
[11] | TIAN Dongxing, PAN Fen, SHI Yingying, JIANG Linlin, GAO Yuan, ZHANG Hong. Serum PCT in the treatment of bloodstream infection in children [J]. Laboratory Medicine, 2019, 34(3): 225-228. |
[12] | CHEN Xiaoyan. Serum procalcitonin level for guiding the discontinuation of antibiotics in patients with urinary sepsis [J]. Laboratory Medicine, 2018, 33(9): 794-797. |
[13] | GU Lei, YANG Yuqin, WANG Xia. PCT and hs-CRP determinations and the combined determination for the diagnosis of neonatal septicemia [J]. Laboratory Medicine, 2018, 33(7): 597-600. |
[14] | WANG Zhaorong, SHAO Xuefeng. Procalcitonin and C-reactive protein in the diagnosis of neonatal bloodstream infection [J]. Laboratory Medicine, 2018, 33(7): 608-611. |
[15] | LIU Shouzhu, ZHAO Haiming. Roles of PCT,DD and MPV determinations in severe acute pancreatitis [J]. Laboratory Medicine, 2018, 33(7): 622-625. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||